Myriam Lucia Hernandez-Rojas, MD (Mexico City, Mexico), Juan Manuel Jimenez-Sierra, MD (Mexico City, Mexico), Hugo Quiroz- Mercado, MD (Mexico City, Mexico), Mitzy Elena Torres-Soriano, MD (Mexico City, Mexico), Jose Luis Diaz-Rubio, MD (Mexico City, Mexico), Victoria Cubas, MD (Mexico City, Mexico), Maria Ana Martinez-Castellanos, MD (Mexico City, Mexico), Jose Luis Guerrero- Naranjo, MD (Mexico City, Mexico), Jans Fromow-Guerra, MD, PhD (Mexico City, Mexico), Virgilio Morales-Canton, MD (Mexico City, Mexico), Daniel Ochoa-Contreras, MD (Mexico City, Mexico)


Bevacizumab is safety to intravitreal treatment?


Open-label, single center, prospective, interventional, uncontrolled clinical study was realized. One hundred and fifty eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received treatment with intravitreal bevacizumab (0.1 ml – 2.5 mg) and underwent pretreatment testing with multifocal electroretinography, repeating the test at 1 and 3 months after initial treatment.


Subjects undergoing mf-ERG testing had no significant changes in electrophysiologic response, although all subjects tested had response improvement in or stabilization of the mf-ERG.


Our results suggest mf-ERG responses in subjects treated with intravitreal injections of bevacizumab showed no significant electrophysiologic abnormalities.